tiprankstipranks
Advertisement
Advertisement

HK:1952 Stock Latest News

Everest Medicines Wins Shareholder Backing for All AGM Resolutions
Company AnnouncementsEverest Medicines Wins Shareholder Backing for All AGM Resolutions
7d ago
1952
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
PremiumCompany Announcements
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
9d ago
1952
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
PremiumCompany Announcements
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
16d ago
1952
Everest Medicines Shareholders Approve Key Share Purchase Agreement
PremiumCompany Announcements
Everest Medicines Shareholders Approve Key Share Purchase Agreement
16d ago
1952
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
PremiumCompany Announcements
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
18d ago
1952
Everest Medicines Substantial Shareholder CBC Group Raises Stake
PremiumCompany AnnouncementsEverest Medicines Substantial Shareholder CBC Group Raises Stake
24d ago
1952
Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
Premium
Company Announcements
Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
26d ago
1952
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
Premium
Company Announcements
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
30d ago
1952
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
PremiumCompany Announcements
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
1M ago
1952
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
PremiumCompany Announcements
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
1M ago
1952
Everest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
PremiumCompany Announcements
Everest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
1M ago
1952
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
PremiumCompany Announcements
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
1M ago
1952
Everest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
PremiumCompany AnnouncementsEverest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
1M ago
1952
Everest Medicines Director and Major Shareholder Raises Stake in Company
Premium
Company Announcements
Everest Medicines Director and Major Shareholder Raises Stake in Company
2M ago
1952
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
Premium
Company Announcements
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
2M ago
1952
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
PremiumCompany Announcements
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
3M ago
1952
Everest Medicines Honorary Chairman Boosts Stake in Company
PremiumCompany Announcements
Everest Medicines Honorary Chairman Boosts Stake in Company
3M ago
1952
Everest Medicines Publishes Audited 2025 Annual Results and Report
PremiumCompany Announcements
Everest Medicines Publishes Audited 2025 Annual Results and Report
3M ago
1952
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
PremiumCompany Announcements
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
3M ago
1952
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
PremiumCompany AnnouncementsEverest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
4M ago
1952
Everest Medicines Sets March 2026 Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
Everest Medicines Sets March 2026 Board Meeting to Approve 2025 Annual Results
4M ago
1952
Everest Medicines Shareholders Approve Commercial Pact and New 2026 Equity Incentive Scheme
Premium
Company Announcements
Everest Medicines Shareholders Approve Commercial Pact and New 2026 Equity Incentive Scheme
4M ago
1952

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >